Lipid Hydroperoxide (LPO) Assay

Confirm delete?

Lipid Hydroperoxide (LPO) Assay Kit

Zoom

Cat No: 705002

Assay Kits - Colorimetric Assays

Quantification of lipid peroxidation is essential to assess the role of oxidative injury in pathophysiological disorders.{1240,2997,4988} Lipid peroxidation results in the formation of highly reactive and unstable hydroperoxides of both saturated and ...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Correlated keywords:

lipids peroxidation oxidative injury inflammation free radicals colorimetric hydroperoxides stress atherosclerosis assays ferroptosis

Product Overview:
Quantification of lipid peroxidation is essential to assess the role of oxidative injury in pathophysiological disorders.{1240,2997,4988} Lipid peroxidation results in the formation of highly reactive and unstable hydroperoxides of both saturated and unsaturated lipids. Our Lipid Hydroperoxide Assay Kit measures the hydroperoxides directly utilizing the redox reactions with ferrous ions.{3237} An easy to use quantitative extraction method was developed to extract lipid hydroperoxides into chloroform, and the extract is directly used in the assay. This procedure eliminates any interference caused by hydrogen peroxide or endogenous ferric ions in the sample and provides a sensitive and reliable assay for lipid peroxidation. This kit is designed for use with either a single-tube spectrophotometer to read the results or with a 96 well microplate reader. The plate used with the microplate reader is a reusable glass plate which is available with the purchase of Item No. 705003. The range of the assay is 0.25-5 nmol hydroperoxide per tube.

Size	100 dtn
Shipping	wet ice
Custom Code	3822.19
UNSPSC code	41116104

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.